PremiumThe FlyCantor starts Viking Therapeutics with Overweight on obesity potential Viking Therapeutics initiated with an Overweight at Cantor Fitzgerald Viking Therapeutics price target lowered to $75 from $95 at Truist PremiumRatingsViking Therapeutics: Strong Financials and Promising VK2735 Program Drive Buy Rating Viking Therapeutics Advances Clinical Pipeline in Q1 2025 Promising Developments and Financial Stability Underpin Buy Rating for Viking Therapeutics PremiumRatingsBuy Rating for Viking Therapeutics Driven by Promising VK2735 Oral GLP-1 Agonist Potential H.C. Wainwright still expects Viking to ‘differentiate’ after Lilly data Eli Lilly jumps as results from weight-loss pill study rival competitor’s 
